Enfuvirtide Acetate (T-20)
vzdevek:Fuzeon
Zaporedje:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas Št. : 159519-65-0
Molekularna formula : C204H301N51O64
Molekulska teža : 4492
Čistost (HPLC) : 98.0%min.
Videz : White to off-white amorphous solid
Ena nečistoča (HPLC) : 0.5%maks
Aminokislinska sestava : ±10 % teoretičnega
Vsebnost peptidov (N %) : ≥80.0%
Vsebnost vode (Karl Fischer) : ≤8.0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
MS (ESI) : Dosledno
Masno ravnotežje : 95.0~105,0 %
Ocena : Farmacevtski razred
Shranjevanje: Zaprto, spodaj 2 ~ 8 ℃ ohranjanje
Uporaba : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (GOSTILNA) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
